Full Press Release Details
INPEFA® (Sotagliflozin) Receives Preferred Formulary Status With Express Scripts For Medicare Patients.
LXRX
INPEFA® (Sotagliflozin) Receives Preferred Formulary Status With Express Scripts For Medicare Patients
Key Takeaway: INPEFA® (Sotagliflozin) Receives Preferred Formulary Status With Express Scripts For Medicare Patients
Price reaction · baseline $1.08 (2023-10-06 close) · 1 other LXRX headline(s) in the window, move may be shared
day 0 close · peak
-7.4%
day 1
+3.7%
day 3
-3.7%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+111%
120-day peak, hindsight
Typical move
11%
average across 13 past catalysts
Cash runway
~61 mo
Minimal dilution risk
Lead asset
Sotagliflozin
Phase 3 · Type 1 Diabetes Mellitus